Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > August 29, 2025
Daily News
August 29, 2025
- Mitsubishi Tanabe Taps Ex-Pfizer Japan Chief as CEO, Ex-Takeda CFO as Chairman
August 29, 2025
- Resilire Seeks to Double Pharma Clients for Supply Chain Visualization Platform
August 29, 2025
- Japan Govt to Spearhead Development of Ultra-Orphan and Infectious Disease Drugs: FY2026 MHLW Budget Request
August 29, 2025
- Novo Hooks Up with Hirosaki City on Obesity Program for Young Adults
August 29, 2025
- Japan Moves Toward OTC Morning-After Pill Sales Without Age Limit or Parental Consent
August 29, 2025
- Indicators Needed to Frame Pharma as Growth Market in Japan, Says JPMA Policy Chief
August 29, 2025
- New PIII Breast Cancer Trial Kicks Off for Daiichi’s HER3 ADC
August 29, 2025
- Sanofi Files for Subcutaneous Formulation of Sarclisa in Japan
August 29, 2025
- Diagnostics Industry Urges Mechanism to Reflect Rising Costs in Reimbursement
August 29, 2025
- AI in Japanese Pharma: Now, Not Later!
August 29, 2025
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…